Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
HyperaBSP:HYPE3 -5.51%92 EV-to-FCF is 11.36 as of Jul. 22, 2026, which is 53% below its 10-year median of 24.43. GuruFocus rates BSP:HYPE3 with a GF Score™ of 92/100 and a GF Value™ of R$32.11 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 567 Drug Manufacturers companies, Hypera ranks better than 73.9% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Hypera's Enterprise Value is R$20,550 Mil.
Hypera's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was R$1,808 Mil. Therefore, Hypera's EV-to-FCF for today is 11.36.
The historical rank and industry rank for Hypera's EV-to-FCF or its related term are showing as below:
BSP:HYPE3'
s EV-to-FCF Range Over the Past 10 Years
Min: -35.27 Med: 24.43 Max: 891.33
Current: 11.73
During the past 13 years, the highest EV-to-FCF of Hypera was 891.33. The lowest was -35.27. And the median was 24.43.
BSP:HYPE3's EV-to-FCF is ranked better than 73.9% of 567
companies
in the Drug Manufacturers industry
Industry Median: 21.08
vs BSP:HYPE3: 11.73
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
As of today (2026-07-22), Hypera's stock price is R$20.24.
Hypera's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was R$2.619. Therefore, Hypera's PE Ratio (TTM) for today is 7.73.
Hypera (BSP:HYPE3) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Hypera's share price for today is R$20.24.
Hypera's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was R$2.619.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Hypera EV-to-FCF Related Terms
Hypera EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Hypera's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BSP:HYPE3 vs ZTS, UTHR, VTRS: EV-to-FCF Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Hypera's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hypera EV-to-FCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Hypera's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Hypera's EV-to-FCF falls into.
Hypera's current Enterprise Value is R$20,550 Mil.
Hypera's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was R$1,808 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hypera (BSP:HYPE3) has a EV-to-FCF of 11.36 as of Jul. 22, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Hypera and its competitors. This is 53% below median its historical median of 24.43. According to the industry distribution chart, Hypera ranks #148 out of 567 companies in the Drug Manufacturers industry, placing it in the top 26.1%.
Is Hypera's EV-to-FCF too high?
Hypera's current EV-to-FCF of 11.36 is 53% below median its 10-year median of 24.43. The Drug Manufacturers industry median EV-to-FCF is 21.08. Hypera's value of 11.36 is 46.1% below this industry median. Based on the distribution chart, Hypera ranks #148 out of 567 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Hypera has a GF Score™ of 92/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Hypera's EV-to-FCF compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Hypera ranks #148 out of 567 companies for EV-to-FCF. This puts Hypera in the upper half of its industry. The industry median EV-to-FCF is 21.08. Hypera's value of 11.36 is 46.1% below this benchmark. While the company's 10-year median is 24.43 vs. the industry median of 21.08, Hypera has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Drug Manufacturers company?
The median EV-to-FCF among Drug Manufacturers companies is 21.08, based on 567 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Hypera's current EV-to-FCF of 11.36 is 46.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Hypera and its competitors. For the Drug Manufacturers industry, the median EV-to-FCF is 21.08 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Hypera's current EV-to-FCF is 11.36, which is 53% below median its own 10-year median of 24.43. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hypera stock overvalued right now?
Based on GuruFocus' analysis, Hypera (BSP:HYPE3) is currently considered Possible Value Trap. The stock's GF Value™ is R$32.11, compared to a current price of R$20.24 — trading 37% below its estimated fair value. The current EV-to-FCF is 11.36, which is 53% below median its 10-year median of 24.43 and 46.1% below the Drug Manufacturers industry median of 21.08. Hypera's overall GF Score™ is 92/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Hypera (BSP:HYPE3), the current EV-to-FCF is 11.36 as of Jul. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Hypera (BSP:HYPE3) Overvalued in 2026?
Based on GuruFocus' analysis, Hypera stock appears to be undervalued.
The current stock price of R$20.24 is trading 37% below its estimated GF Value™ of R$32.11.
GuruFocus considers Hypera to be Possible Value Trap.
Key valuation signals for BSP:HYPE3:
EV-to-FCF: 11.36 (53% below median its 10-year median of 24.43)
GF Value™: R$32.11 vs. price of R$20.24 (37% below fair value)
Industry Position: 46.1% below the Drug Manufacturers median (#148 of 567)
No single metric tells the full story. See the BSP:HYPE3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Hypera SA is a specialty and generic drug manufacturing company. The company operates in the prescription medicines, over-the-counter (OTC) medicines, branded generics, and generics, and skincare segments within the retail pharmaceutical market. The company also has a wide sales and distribution structure. The company's product portfolio includes key brands in Gastroenterology, Pain, Sun Protection, Skin Moisture, and Cleansing within the over-the-counter (OTC) and Skincare segments, as well as new products in Cardiology, Central Nervous System, and Respiratory System within the prescription medicines segment.
92GF Score
Get the complete analysis for BSP:HYPE3
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BSP:HYPE3 has been successfully added to your 
